Phytopharm plc (LSE: PYM) (”Phytopharm” or the “Company”) announces today that it has successfully completed a Phase Ib healthy volunteer clinical study for Myogane™. Myogane™ is a novel orally active neurotrophic factor inducer being developed for orphan motor neurone diseases of which the most prevalent form is amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s disease).
